Back to results
US 11,684,569 B2Granted
Dendrimers for sustained release of compounds
AssigneeWayne State University
InventorsKannan Rangaramanujam, Raymond Iezzi, Bharath Raja Guru, Sujatha Kannan
Life of this patent
Estimating the term…
Abstract
Dendrimer-based compositions and methods are provided, that are useful for administering pharmaceutical compositions to target cells and tissues for treatment of ocular diseases including macular degeneration, diabetic retinopathy, and retinitis pigmentosa.
Claims7
A method of treating microglia or macrophage-mediated ocular neuroinflammation in a subject in need thereof, the method comprising:
- intravitreally administering to the subject a dendrimer-drug conjugate comprising a generation 4 (G4) polyamidoamine (PAMAM) dendrimer with free hydroxyl terminal groups and one or more biologically active agents conjugated thereto, wherein the inflammation is caused by a disease or disorder of the retina,
- wherein the dendrimer-drug conjugate is selectively taken up by activated microglial cells or macrophages at a site of ocular neuroinflammation, and
- wherein the dendrimer-drug conjugate is in an amount effective to provide sustained release of the one or more biologically active agents for at least one month at the site of ocular neuroinflammation.
Dependencies are inferred from the claim text.